Cognitive impairments in common and rare somatic diseases
Abstract
The paper gives an update on the pathogenesis, clinical presentation, and pathomorphology of cognitive impairments (CIs) in different autoimmune, endocrine, and infectious diseases, such as systemic lupus erythematosus, Sjögren's syndrome, BehНet's disease, primary angiitis of the central nervous system, polyarteritis nodosa, cryoglobulinemic vasculitis, hypothyroidism, herpetic lesion, and neurosyphilis. These patients are observed to have ischemic-hypoxic brain damage, the causes of which are free radical-induced cell injury, oxidative stress, excitation toxicity, cell necrosis and/or apoptosis, inflammation and immune disease, molecular sequestration, and cell death. There is enhanced imbalance in the pro-oxidant and antioxidant systems as cerebrovascular insufficiency progresses; as this takes place, the nerve cells are most susceptible to the induction of free radical reactions. In these cases, antioxidants that block the effects of free radicals and may potentially improve brain perfusion, by assisting the coupling of neurons and vessels, are first-choice drugs. To improve the cognitive status and to prevent the progression of CIs, it is important to build a cognitive reserve in a patient; this is largely favored by the preservation of a proactive approach to life and social bonds, as well as intellectual work.
About the Author
Natalia Vyacheslavovna Pizova
Yaroslavl State Medical University, Ministry of Health of
Russia
Russian Federation
Russian Federation
Department of Neurology and Medical Genetics with Course of Neurosurgery,
5, Revolutsionnaya St., Yaroslavl 150000
References
1. Парфенов ВА, Неверовский ДВ. Ведение пациентов с дисциркуляторной энцефалопатией в амбулаторной практике. Неврология, нейропсихиатрия, психосоматика. 2015;7(1):37-42. [Parfenov VA, Neverovskii DV. Outpatient management of patients with dyscirculatory encephalopathy. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, neuropsychiatry, psychosomatics. 2015;7(1):37-42. (In Russ.)]. DOI: http://dx.doi.org/10.14412/2074-2711-2015-1-37-42
2. Пизова НВ, Данилова МВ. Когнитивные нарушения в клинической практике и анализ работы кабинета нарушений памяти в Ярославле (амбулаторный прием). Неврология, нейропсихиатрия, психосоматика. 2014;6(3):32-7. [Pizova NV, Danilova MV. Cognitive impairments in clinical practice and analyzing the work of a memory room in Yaroslavl (an outpatient reception). Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, neuropsychiatry, psychosomatics. 2014;6(3):32-7. (In Russ.)]. DOI: http://dx.doi.org/10.14412/2074-2711-2014-3-32-37
3. Пизова НВ. Энцефалопатии в неврологической практике. Справочник поликлинического врача. 2014;(6):30-5. [Pizova NV. Encephalopathies in neurological practice. Spravochnik poliklinicheskogo vracha. 2014;(6):30-5. (In Russ.)].
4. The American College of Rheumatology nomenclature and care definitions for neuropsychiatric lupus syndromes. Arthritis Rheum. 1999 Apr;42(4):599-608.
5. Carbotte RM, Denburg SD, Denburg JA. Prevalence of cognitive impairment in systemic lupus erythematosus. J Nerv Ment Dis. 1986 Jun;174(6):357-64.
6. Carlomagno S, Migliaresi S, Ambrosone L, et al. Cognitive impairment in systemic lupus erythematosus: a follow-up study. J Neurol. 2000 Apr;247(4):273-9.
7. Glanz BI, Slonim D, Urowitz MB, et al. Pattern of neuropsychological dysfunction in inactive systemic lupus erythematosus. Neuropsychiatry Neuropsychol Behav Neurol. 1997 Oct;10(4):232-8.
8. Hanly JG, Fisk JD, Sherwood G, et al. Cognitive impairment in patients with systemic lupus erythematosus. J Rheumatol. 1992 Apr;19(4):562-7.
9. Hay EM, Black D, Huddy A, et al. Psychiatric disorder and cognitive impairment in systemic lupus erythematosus. Arthritis Rheum. 1992 Apr;35(4):411-6.
10. Kozora E, Thompson LL, West SG, Kotzin BL. Analysis of cognitive and psychological deficits in systemic lupus erythematosus patients without overt central nervous system disease. Arthritis Rheum. 1996 Dec;39(12):2035-45.
11. Brey RL, Holliday SL, Saklad AR, et al. Neuropsychiatric syndromes in lupus. Prevalence using standardized definitions. Neurology. 2002 Apr 23;58(8):1214-20.
12. Mok CC, To CH, Mak A. Neuropsychiatric damage in Southern Chinese patients with systemic lupus erythematosus. Medicine (Baltimore). 2006 Jul;85(4):221-8.
13. Пизова НВ. Когнитивные нарушения при системной красной волчанке. Журнал неврологии и психиатрии им. С.С. Корсакова. 2013;12(113):113-7. [Pizova NV. Cognitive impairment in systemic lupus erythematosus. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2013;12(113):113-7. (In Russ.)].
14. McLaurin EY, Holliday SL, Williams P, Brey RL. Predictors of cognitive dysfunction in patients with systemic lupus erythematosus. Neurology. 2005 Jan 25;64(2):297-303.
15. Gladman DD, Urowitz MB, Slonim D, et al. Evaluation of predictive factors for neurocognitive dysfunction in patients with inactive systemic lupus erythematosus. J Rheumatol. 2000 Oct;27(10):2367-71.
16. Carbotte RM, Denburg SD, Denburg JA. Cognitive dysfunction in systemic lupus erythematosus is independent of active disease. J Rheumatol. 1995 May;22(5):863-7.
17. Rogers MP, Waterhouse E, Nagel JS, et al. I-123 iofetamine SPECT scan in systemic lupus erythematosus patients with cognitive and other minor neuropsychiatric symptoms: a pilot study. Lupus. 1992 Aug;1(4):215-9.
18. Tomietto P, Annese V, D'Agostini S, et al. Neuropsychological tests, MRI and SPECT in the evaluation of CNS involvement in SLE. Reumatismo. 2003;55(3):171-80.
19. Waterloo K, Omdal R, Sjoholm H, et al. Neuropsychological dysfunction in systemic lupus erythematosus is not associated with changes in cerebral blood flow. J Neurol. 2001 Jul;248(7):595-602.
20. Hanly JG, Hong C, Smith S, Fisk JD. A prospective analysis of cognitive function and anticardiolipin antibodies in systemic lupus erythematosus. Arthritis Rheum. 1999 Apr;42(4):728-34.
21. Long AA, Denburg SD, Carbotte RM, et al. Serum lymphocytotoxic antibodies and neurocognitive function in systemic lupus erythematosus. Ann Rheum Dis. 1990 Apr;49(4):249-53.
22. Isshi K, Hirohata S. Differential roles of the anti-ribosomal P antibody and anti-neuronal antibody in the pathogenesis of central nervous system involvement in systemic lupus erythematosus. Arthritis Rheum. 1998 Oct;41(10):1819-27.
23. Tzioufas AG, Tzortzakis NG, Panou-Pomonis E, et al. The clinical relevance of antibodies to ribosomal-P common epitope in two targeted systemic lupus erythematosus populations: a large cohort of consecutive patients and patients with active central nervous system disease. Ann Rheum Dis. 2000 Feb;59(2):99-104.
24. Shucard JL, Gaines JJ, Ambrus J, et al. C-reactive protein and cognitive deficits in systemic lupus erythematosus. Cogn Behav Neurol. 2007 Mar;20(1):31-7.
25. Asherson RA, Mercey D, Phillips G, et al. Recurrent stroke and multi-infarct dementia in systemic lupus erythematosus: association with antiphospholipid antibodies. Ann Rheum Dis. 1987 Aug;46(8):605-11.
26. Пизова НВ. Первичные системные васкулиты и поражение центральной нервной системы. Журнал неврологии и психиатрии им. С.С. Корсакова. 2014;(3):98-102. [Pizova NV. Primary systemic vasculitis and disorders of central nervous system. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2014;(3):98-102. (In Russ.)].
27. Joseph FG, Scolding NJ. Cerebral vasculitis: a practical approach. Pract Neurol 2002; 2:80-93.
28. Салихов ИГ, Богданов ЭИ, Заббарова АТ, Васильева АВ. Принципы диагностики церебральных васкулитов. Казань; 2001. 27 с. [Salikhov IG, Bogdanov EI, Zabbarova AT, Vasil'eva AV. Printsipy diagnostiki tserebral'nykh vaskulitov [Principles of diagnosis of cerebral vasculitis]. Kazan; 2001. 27 p.]
29. Ferro JM. Vasculitis of the central nervous system. J Neurol. 1998 Dec;245(12):766-76.
30. Sampson EL, Warren JD, Rossor MN. Youngonset dementia. Postgrad Med J. 2004 Mar;80(941):125-39.
31. Siva A. Vasculitis of the nervous system. J Neurol. 2001 Jun;248(6):451-68.
32. Cid MC, Garcia-Martinez A, Lozano E, et al. Five clinical conundrums in the management of giant-cell arteritis. Rheum Dis Clin North Am. 2007 Nov;33(4):819-34, vii.
33. Cid MC, Prieto-Gonzalez S, Arguis P, et al. The spectrum of vascular involvement in giantcell arteritis: clinical consequences of detrimental vascular remodelling at different sites. APMIS Suppl. 2009 Jun;(127):10-20. doi: 10.1111/j.1600-0463.2009.02471.x.
34. Gonzalez-Gay MA, Vazquez-Rodriguez TR, Gomez-Acebo I, et al. Strokes at time of disease diagnosis in a series of 287 patients with biopsy-proven giant cell arteritis. Medicine
35. (Baltimore). 2009 Jul;88(4):227-35. doi: 10.1097/MD.0b013e3181af4518.
36. Solans-Laque R, Bosch-Gil JA, Molina-Catenario CA, et al. Stroke and multiinfarct dementia as presenting symptoms of giant cell arteritis, report of 7 cases and review of the literature. Medicine (Baltimore). 2008 Nov;87(6):335-44. doi: 10.1097/MD.0b013e3181908e96.
37. Alexander EL, Ranzenbach MR, Kumar AJ, et al. Anti-Ro(SS-A) autoantibodies in central, nervous system disease associated with Sjö gren's syndrome (CNS-SS): clinical, neuroimaging, and angiographic correlates. Neurology. 1994 May;44(5):899-908.
38. Caselli RJ1, Scheithauer BW, Bowles CA, et al. The treatable dementia of SjЪgren's syndrome. Ann Neurol. 1991 Jul;30(1):98-101.
39. Mauch E, Volk C, Kratzsch G, et al. Neurological and neuropsychiatric dysfunction in primary SjЪgren's syndrome. Acta Neurol Scand. 1994 Jan;89(1):31-5.
40. Motomura S, Tabira T, Kuroiwa Y. A clinical comparative study of multiple sclerosis and Neuro-Behcet's syndrome. J Neurol Neurosurg Psychiatry. 1980 Mar;43(3):210-3.
41. Robin C, Gonnaud PM, Durieu I, et al. Progressive lupus dementia. 2 cases with or without antiphospholipid antibodies. Rev Neurol (Paris). 1995 Dec;151(12):699-707.
42. Rosenberg MR, Parshley M, Gibson S, Wernick R. Central nervous system polyarteritis nodosa. West J Med. 1990 Nov;153(5):553-6.
43. Casato M, Saadoun D, Marchetti A, et al. Central nervous system involvement in hepatitis C virus cryoglobulinemia vasculitis, a multicenter casecontrol study using magnetic resonance imaging and neuropsychological tests. J Rheumatol. 2005 Mar;32(3):484-8.
44. Salvarani C, Brown RD, Calamia KT, et al. Primary central nervous system vasculitis, analysis of 101 patients. Ann Neurol. 2007 Nov;62(5):442-51.
45. Пизова НВ. Первичный (изолированный) ангиит ЦНС. Медицинский совет. 2013;(4):79-82. [Pizova NV. Primary (isolated) vasculitis of the Central nervous system. Meditsinskii sovet. 2013;(4):79-82. (In Russ.)].
46. Пизова НВ, Вербицкая ЕИ, Пережигина НВ, Пизов АВ. Память, внимание, индивидуальный профиль межполушарной асимметрии у пациентов с системными ревматическими заболеваниями. Анналы клинической и экспериментальной неврологии. 2010;4(2):35-40. [Pizova NV, Verbitskaya EI, Perezhigina NV, Pizov AV. Memory, attention, individual profile of interhemispheric asymmetry in patients with systemic rheumatic diseases. Annaly klinicheskoi i eksperimental'noi nevrologii. 2010;4(2):35-40. (In Russ.)].
47. Smith JW, Evans AT, Costall B, Smythe JW. Thyroid hormones, brain function and cognition: a brief review. Neurosci Biobehav Rev. 2002 Jan;26(1):45-60.
48. Abend WK, Tyler HR. Thyroid disease and the Nervous System. In: Neurology and General Medicine. The Neurological Aspects of Medical Disorders. Second edition. Aminoff MJ, editor. Chapter 18. New York etc.: Churchill Livingstone; 1995. P. 333-47.
49. Дамулин ИВ, Оразмурадов ГО. Неврологические нарушения при гипотиреозе. Журнал неврологии и психиатрии им. С.С. Корсакова. 2011;111(3):82-6. [Damulin IV, Orazmuradov GO. Neurological disorders in hypothyroidism. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2011;111(3):82-6. (In Russ.)].
50. Greenberg DA, Aminoff MJ, Simon RP. Clinical Neurology. Fifth edition. Chapter 1: Disorders of Consciousness. New York etc.: Lange Medical Books. McGraw-Hill; 2002. P. 1-70.
51. Hokkanen L, Launes J. Cognitive outcome in acute sporadic encephalitis. Neuropsychol Rev. 2000 Sep;10(3):151-67.
52. Sachdev P, Trollor J, Looi JC. Treatment of reversible or arrestable dementias. In: Evidencebased Dementia Practice. Qizilbash N, editor. Oxford: Blackwell Sciences; 2002. P. 615-38.
53. Pryse-Phillips W, Wahlund LO. Other dementias. In: Diagnosis and Management of Dementia. A Manual for Memory Disorders Teams. Wilcock GK, editor. Oxford: Oxford University Press; 1999. P. 252-76.
54. Дамулин ИВ. Вторичные деменции (когнитивные расстройства при травматических и опухолевых поражениях головного мозга, при инфекционных и аутоимунных заболеваниях). Методическое пособие для врачей. Москва;, 2009. 42 с. [Damulin IV. Vtorichnye dementsii (kognitivnye rasstroistva pri travmaticheskikh i opukholevykh porazheniyakh golovnogo mozga, pri infektsionnykh i autoimmunnykh zabolevaniyakh). Metodicheskoe posobie dlya vrachei [Secondary dementia (cognitive disorders in traumatic and tumoral brain lesions, infectious and autoimmune diseases). Methodological manual for doctors]. Moscow; 2009. 42 p.]
55. Hem E, Small T, Opjordsmoen S, Myrvang B. Neurosyphilis-still a relevant differential diagnosis. Tidsskr Nor Laegeforen. 1999 Jun 30;119(17):2469-71.
56. Kararizou E, Mitsonis C, Dimopoulos N, et al. Psychosis or simply a new manifestation of neurosyphilis? J Int Med Res. 2006 MayJun;34(3):335-7.
57. Mahmoudi R, Maheut-Bosser A, Hanesse B, Paille F. Neurosyphilis: a rare cause of dementia. Rev Med Interne. 2006 Dec;27(12):976-8. Epub 2006 Aug 18.
58. Silva A, Arrojo M, Ferreira P, et al. Interface neurology/psychiatry: a case report of neurosyphilis. Actas Esp Psiquiatr. 2003 JulAug;31(4):231-3.
59. Sobhan T, Rowe HM, Ryan WG, Munoz C. Unusual case report: three cases of psychiatric manifestations of neurosyphilis. Psychiatr Serv. 2004 Jul;55(7):830-2.
60. Timmermans M, Carr J. Neurosyphilis in the modern era. J Neurol Neurosurg Psychiatry. 2004 Dec;75(12):1727-30.
61. Carr J. Neurosyphilis. Pract Neurol. 2003;3:328-341.
62. Uribe CS, Garcia FA. Neurosyphilis and the prozone effect. Rev Neurol. 1998 Dec;27(160):970-2.
63. Vargas AP, Carod-Artal FJ, Del Negro MC, Rodrigues MP. Dementia caused by neurosyphilis: clinical and neuropsychological follow-up of a patient. Arq Neuropsiquiatr. 2000 Jun;58(2B):578-82.
64. Zifko U, Wimberger D, Lindner K, et al. MRI in patients with general paresis. Neuroradiology. 1996 Feb;38(2):120-3.
65. Tada Y, Mizutani T, Nishimura T, et al. Acute bilateral cerebellar infarction in the territory of the medial branches of posterior interior cerebellar arteries. Stroke. 1994 Mar;25(3):686-8.
66. Sorenson EJ, Wijdicks EF, Thielen KR, Cheng TM. Acute bilateral infarcts of the posterior inferior cerebellar artery. J Neuroimaging. 1997 Oct;7(4):250-1.
67. Scheid R. Differential diagnosis of mesiotemporal lesions: case report of neurosyphilis. Neuroradiology. 2006 Jul;48(7):506; author reply 507. Epub 2006 Mar 28.
68. Rentrop M, Häussermann P, Wilhelm T, et al. Brain stem and cerebellar atrophy in eurosyphilis. Nervenarzt. 2001 Aug;72(8):647-51.
69. Van Eijsden P, Veldink JH, Linn FH, et al. Progressive dementia and mesiotemporal atrophy on brain MRI: neurosyphilis mimicking pre-senile Alzheimer's disease? Eur J Neurol. 2008 Feb;15(2):e14-5. Epub 2007 Dec 18.
70. Гаврилова СИ. Фармакотерапия болезни Альцгеймера. Москва: Медиасфера; 2007. 360 c. [Gavrilova SI. Farmakoterapiya bolezni Al'tsgeimera [Pharmacotherapy of Alzheimer's disease]. Moscow: Mediasfera; 2007. 360 p.]
71. Дамулин ИВ. Болезнь Альцгеймера и сосудистая деменция. Яхно НН, редактор. Москва; 2002. 86 с. [Damulin IV. Bolezn' Al'tsgeimera i sosudistaya dementsiya [Alzheimer's disease and vascular dementia]. Yakhno NN, editor. Moscow; 2002. 86 p.]
72. Захаров ВВ, Яхно НН. Нарушеня памяти. Москва; 2003. 150 с. [Zakharov VV, Yakhno NN. Narusheniya pamyati [Memory impairment]. Moscow; 2003. 150 p.]
73. Левин ОС. Диагностика и лечение деменции в клинической практике. Москва: МЕДпресс-информ; 2010. 256 с. [Levin OS. Diagnostika i lechenie dementsii v klinicheskoi praktike [Diagnosis and treatment of dementia in clinical practice]. Moscow: MEDpressinform; 2010. 256 p.]
74. Andrieux S, Amouyal K, Renish W, et al. The consumption of vasodilators and Ginkgo biloba (Egb 761) in a population of 7598 women over the age of 75 years. Res and pract Alzheimer's disease 2001;5:57-68.
75. Молодавкин ГМ, Борликова ГГ, Воронина ТА и др. Влияние нового дипептидного ноотропа и его метаболита цикло-L-пролилглицина на транскаллозальный потенциал мозга крыс. Экспериментальная и клиническая фармакология. 2002;65(2):3-5. [Molodavkin GM, Borlikova GG, Voronina TA, et al. The effect of new nootropic dipeptide and its metabolite cyclo-L-polyglycine on transcallosal potential of the rat brain. Eksperimental'naya i klinicheskaya farmakologiya. 2002;65(2):3-5. (In Russ.)].
76. Преображенская ИС. Ноотропные препараты в гериатрической практике. Русский медицинский журнал. 2004;5(12):256-61. [Preobrazhenskaya IS. Nootropic drugs in geriatric practice. Russkii Meditsinskii Zhurnal. 2004;5(12):256-61. (In Russ.)].
77. Knopman DS. Current treatment of mild cognitive impairment and Alzheimer’s disease. Curr Neurol Neurosci Rep. 2006 Sep;6(5):365-71.
78. Wilson HC, Scolding N. Inflammatory and infective disorders. In: Early-Onset Dementia. A Multidisciplinary Approach. Hodges JR, editor. Oxford University Press; 2001. P. 385-403.
79. Clemens JA. Cerebral ischemia gene activation,neuronal injury, and the protective role of antioxidants. Free Radic Biol Med. 2000 May 15;28(10):1526-31.
80. Pasker LL, Prilipco Y, CyistenY. Free radicalisin the brain. Berlin; 1992. 120 p.
81. Беленичев ИФ. Отчет о НИР «Исследование безвредности и специфического действия таблеток «Тиоцетам» с измененным составом оболочки». Запорожье; 2004. 21 с. [Belenichev IF. Otchet o NIR «Issledovanie bezvrednosti i spetsificheskogo deistviya tabletok «Tiotsetam» s izmenennym sostavom obolochki» [Study of harmlessness and specific actions of «Tiocetam» with a modified shell]. Zaporozh'e; 2004. 21 p.]
82. Беленичев ИФ. Отчет о НИР «Изучение нейропротективной и ноотропной активности препарата Тиоцетам в условиях моделирования фетоплацентарной недостаточности». Запорожье; 2009. 44 с. [Belenichev IF. Otchet o NIR «Izuchenie neiroprotektivnoi i nootropnoi aktivnosti preparata Tiotsetam v usloviyakh modelirovaniya fetoplatsentarnoi nedostatochnosti» [The study of neuroprotective and nootropic activity of Tiocetam in terms of modeling placental insufficiency]. Zaporozh'e; 2009. 44 p.]
83. Волошин НА, Визир ВА, Волошина ИН. Тиотриазолин, тиоцетам, тиодарон в практике врача. Запорожье: ЗГМУ; 2008. 220 с. [Voloshin NA, Vizir VA, Voloshina IN. Tiotriazolin, tiotsetam, tiodaron v praktike vracha [Thiotriazolin, tiocetam, tiodaron in the practice of medical]. Zaporozh'e: ZGMU; 2008. 220 p.]
84. Дайникова ЕИ, Пизова НВ. Когнитивный резерв и когнитивные нарушения: лекарственные и нелекарственные методы коррекции. Неврология, нейропсихиатрия, психосоматика. 2014;6(спецвыпуск 2):62–8. [Dainikova EI, Pizova NV. Cognitive reserve and cognitive impairments: drug and nondrug treatments. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, neuropsychiatry, psychosomatics. 2014;6(S2):62–8. (In Russ.)]. DOI: http://dx.doi.org/10.14412/2074-2711-2014-2S-62-68
For citation:
Pizova N.V. Cognitive impairments in common and rare somatic diseases. Neurology, Neuropsychiatry, Psychosomatics. 2015;7(3):86-92. (In Russ.) https://doi.org/10.14412/2074-2711-2015-3-86-92
Views: 518
Email this article 